ATE77958T1 - Aktivierung der tumorzerstoerenden aktivitaet der makrophagen mittels des granulozyten-makrophagen- kolonien stimulierenden faktors. - Google Patents

Aktivierung der tumorzerstoerenden aktivitaet der makrophagen mittels des granulozyten-makrophagen- kolonien stimulierenden faktors.

Info

Publication number
ATE77958T1
ATE77958T1 AT86306304T AT86306304T ATE77958T1 AT E77958 T1 ATE77958 T1 AT E77958T1 AT 86306304 T AT86306304 T AT 86306304T AT 86306304 T AT86306304 T AT 86306304T AT E77958 T1 ATE77958 T1 AT E77958T1
Authority
AT
Austria
Prior art keywords
granulocyte
stimulating factor
colony stimulating
macrophage colony
macrophage
Prior art date
Application number
AT86306304T
Other languages
English (en)
Inventor
Dirk M Anderson
Michael A Cantrell
Douglas P Cerretti
Paul J Conlon Iii
David J Cosman
Kenneth H Grabstein
Alf D Larsen
Virginia L Price
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27117812&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE77958(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of ATE77958T1 publication Critical patent/ATE77958T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT86306304T 1985-08-16 1986-08-15 Aktivierung der tumorzerstoerenden aktivitaet der makrophagen mittels des granulozyten-makrophagen- kolonien stimulierenden faktors. ATE77958T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76689385A 1985-08-16 1985-08-16
US06/888,995 US5078996A (en) 1985-08-16 1986-07-31 Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
EP86306304A EP0211684B1 (de) 1985-08-16 1986-08-15 Aktivierung der tumorzerstörenden Aktivität der Makrophagen mittels des Granulozyten-Makrophagen-Kolonien stimulierenden Faktors

Publications (1)

Publication Number Publication Date
ATE77958T1 true ATE77958T1 (de) 1992-07-15

Family

ID=27117812

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86306304T ATE77958T1 (de) 1985-08-16 1986-08-15 Aktivierung der tumorzerstoerenden aktivitaet der makrophagen mittels des granulozyten-makrophagen- kolonien stimulierenden faktors.

Country Status (8)

Country Link
US (1) US5078996A (de)
EP (1) EP0211684B1 (de)
JP (1) JPH0780781B2 (de)
AT (1) ATE77958T1 (de)
AU (1) AU586876B2 (de)
CA (1) CA1341142C (de)
DE (1) DE3685918T2 (de)
DK (1) DK174603B1 (de)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2130493C1 (ru) * 1984-07-06 1999-05-20 Новартис Аг Способ получения белка с активностью gm-csf приматов
US5795568A (en) * 1984-09-19 1998-08-18 Novartis Corporation Method of treating infectious disease with GM-CSF
US5837229A (en) * 1985-02-05 1998-11-17 Chiron Corporation Uses of recombinant colony stimulating factor-1
US5104650A (en) * 1985-02-05 1992-04-14 Cetus Corporation Uses of recombinant colony stimulating factor-1
US5556620A (en) * 1985-02-05 1996-09-17 Cetus Oncology Corporation Use of recombinant colony stimulating factor-1 to enhance wound healing
US5422105A (en) * 1985-02-05 1995-06-06 Cetus Oncology Corporation Use of recombinant colony stimulating factor 1
US5093115A (en) * 1985-06-11 1992-03-03 The United States Of America As Represented By The Department Of Health And Human Services Method of preparing activated killer monocytes for treating colorectal cancer
US5391706A (en) * 1987-07-16 1995-02-21 Schering Plough Corporation Purification of GM-CSF
IL88344A (en) * 1987-11-12 1994-06-24 Schering Corp Accelerating bone formation using a factor that accelerates colonies of granulocyte macrophages
BE1002141A5 (fr) * 1988-01-13 1990-07-31 Bartholeyns Jacques Procede de culture et d'activation de cellules humaines et conditionnement pour le traitement du cancer.
JPH01193227A (ja) * 1988-01-29 1989-08-03 Res Dev Corp Of Japan 癌免疫療法補助剤
WO1990001942A1 (en) * 1988-08-19 1990-03-08 Genetics Institute, Inc. Treatment for malignant melanoma
GB8824591D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
DK0382381T3 (da) * 1989-01-30 1993-07-12 Schering Corp Behandling af leukocyt-dysfunktion med GM-CSF
US5154921A (en) * 1990-07-13 1992-10-13 Dana-Farber Cancer Institute, Inc. Promotion of maturation of hematopoietic progenitor cells
US5199942A (en) * 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
US5904920A (en) * 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
US5637483A (en) * 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
US5292513A (en) * 1992-05-18 1994-03-08 Anthony G. Gristina Method for nonspecific cellular immune stimulation
US6001351A (en) * 1993-05-18 1999-12-14 I.D.M. Immuno-Designed Molecules Macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions
US5662899A (en) * 1993-05-18 1997-09-02 I.D.M. Immuno-Designed Molecules Macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions
US6540994B1 (en) * 1997-07-18 2003-04-01 I.D.M. Immuno-Designed Molecules Macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions
CA2227241C (en) * 1995-07-21 2004-12-21 THE GOVERNMENT OF THE UNITED STATES, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Method of decreasing radiation or radio-mimetic chemotherapy for hematopoietic pluripotent cell engraftment
US6267955B1 (en) 1995-09-15 2001-07-31 Yeda Research And Development Co. Ltd. Mononuclear phagocytes and their use to promote axonal regeneration
US5800812A (en) * 1995-09-15 1998-09-01 Yeda Research And Development Co. Ltd. Methods of use of mononuclear phagocytes to promote axonal regeneration
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US6080409A (en) * 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
US5891432A (en) 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
WO2000026676A1 (en) * 1998-11-03 2000-05-11 Cell Genesys, Inc. Cancer-associated antigens and methods of their identification
ID30407A (id) 1999-05-13 2001-11-29 American Cyanamid Co Formulasi-formulasi kombinasi bahan penambah
CA2388301C (en) 1999-10-22 2011-01-04 Aventis Pasteur Limited Modified gp100 and uses thereof
SG143058A1 (en) * 2000-08-11 2008-06-27 Favrille Inc Method and composition for altering a t cell mediated pathology
US6911204B2 (en) 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
WO2002038177A2 (en) * 2000-11-10 2002-05-16 Wyeth Holdings Corporation Adjuvant combination formulations
US20070128229A1 (en) * 2002-04-12 2007-06-07 Wyeth Surface proteins of Streptococcus pyogenes
CN101124237A (zh) * 2001-04-13 2008-02-13 惠氏 酿脓链球菌的表面蛋白
KR100886095B1 (ko) 2001-04-16 2009-02-27 와이어쓰 홀딩스 코포레이션 폴리펩티드 항원을 암호화하는 신규한 스트렙토코쿠스 뉴모니애 개방형 판독 프레임 및 이를 포함하는 조성물
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CA2479118A1 (en) * 2002-03-15 2003-09-25 Wyeth Holdings Corporation Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US7301554B2 (en) * 2002-09-20 2007-11-27 Ricoh Company, Ltd. Light scanning device, scanning line adjusting method, scanning line adjusting control method, image forming apparatus, and image forming method
WO2004035086A2 (en) 2002-10-16 2004-04-29 Hunter Samuel F Method for treatment of demyelinating central nervous system disease using gm-csf
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
US8071652B2 (en) * 2003-08-21 2011-12-06 The Board Of Regents Of The University Of Texas System Method of treating irritable bowel syndrome
SG149013A1 (en) 2003-12-17 2009-01-29 Wyeth Corp Immunogenic peptide carrier conjugates and methods of producing same
SI2336147T1 (sl) 2003-12-17 2014-08-29 Janssen Alzheimer Immunotherapy Konjugati nosilcev a beta imunogenih peptidov in postopki izdelave istih
ATE451924T1 (de) 2004-03-15 2010-01-15 Sunesis Pharmaceuticals Inc Sns-595 und anwendungsverfahren
GB0410220D0 (en) 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
US7674456B2 (en) * 2004-06-14 2010-03-09 Charles Wiseman Breast cancer cell lines and uses thereof
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
WO2006019950A2 (en) * 2004-07-16 2006-02-23 Nektar Therapeutics Al, Corporation Conjugates of a gm-csf moiety and a polymer
US20060062764A1 (en) * 2004-08-25 2006-03-23 Seshidar-Reddy Police Fiber-modified adenoviral vectors for enhanced transduction of tumor cells
US20060057127A1 (en) * 2004-09-10 2006-03-16 Pocheng Liu Cytokine-expressing cellular vaccines for treatment of prostate cancer
BRPI0516974A (pt) 2004-10-21 2008-09-30 Wyeth Corp composição imunogênica compreendendo um polipeptìdeo; um método para induzir uma resposta imune contra staphylococcus epidermidis; um método para induzir uma resposta imune contra staphylococcus aureus; um método para a detecção e/ou identificação de staphylococcus epidermidis; um método para a detecção e/ou identificação de anticorpos para staphylococcus epidermidis
WO2006050058A2 (en) * 2004-10-28 2006-05-11 The General Hospital Corporation Methods of detection and therapy of inflamed tissues using immune modulation
WO2006049599A1 (en) * 2004-10-28 2006-05-11 The General Hospital Corporation Methods of detection and therapy for atheromatous plaques using immune modulation
RU2271392C1 (ru) * 2004-11-15 2006-03-10 Институт Биоорганической химии им. акад. М.М. Шемякина и Ю.А. Овчинникова Российской Академии Наук РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pFGM17, КОДИРУЮЩАЯ ПОЛИПЕПТИД ГРАНУЛОЦИТАРНО-МАКРОФАГАЛЬНОГО КОЛОНИЕСТИМУЛИРУЮЩЕГО ФАКТОРА ЧЕЛОВЕКА, И ШТАММ БАКТЕРИЙ Escherichia coli BL21(DE3)/pFGM17 - ПРОДУЦЕНТ ПОЛИПЕПТИДА ГРАНУЛОЦИТАРНО-МАКРОФАГАЛЬНОГО КОЛОНИЕСТИМУЛИРУЮЩЕГО ФАКТОРА ЧЕЛОВЕКА
US8580814B2 (en) * 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
WO2007123737A2 (en) 2006-03-30 2007-11-01 University Of California Methods and compositions for localized secretion of anti-ctla-4 antibodies
US7919079B2 (en) * 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
US20070231298A1 (en) * 2006-03-31 2007-10-04 Cell Genesys, Inc. Cytokine-expressing cancer immunotherapy combinations
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8124773B2 (en) * 2006-06-12 2012-02-28 Sunesis Pharmaceuticals, Inc. 1,8-naphthyridine compounds for the treatment of cancer
DK2041270T3 (da) 2006-07-13 2014-01-27 Wyeth Llc Fremstilling af glycoproteiner
MX2009004519A (es) 2006-11-03 2009-05-12 Wyeth Corp Sustancias que inhiben la glucolisis en un cultivo de celulas.
US20090285819A1 (en) * 2006-11-15 2009-11-19 Functional Genetics, Inc. Methods and compositions for treating influenza
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
CA2679941C (en) 2007-03-02 2016-09-20 Wyeth Use of copper and glutamate in cell culture for production of polypeptides
WO2008109818A1 (en) * 2007-03-07 2008-09-12 Mayo Foundation For Medical Education And Research Treating cancer with granulocyte-macrophage colony stimulating factor
US20100255513A1 (en) * 2007-03-30 2010-10-07 Denson Lee A Serological markers of inflammatory bowel disease phenotype and disease progression
US20080267935A1 (en) * 2007-04-06 2008-10-30 Cell Genesys, Inc. AraC in combination with a cytokine-secreting cell and methods of use thereof
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
WO2009032256A2 (en) * 2007-08-30 2009-03-12 Cell Genesys, Inc. Apc activators in combination with a cytokine-secreting cell and methods of use thereof
WO2009082664A2 (en) * 2007-12-21 2009-07-02 Wyeth Genetically modified attenuated vesicular stomatitis virus, compositions and methods of use thereof
WO2009155484A2 (en) 2008-06-20 2009-12-23 Wyeth Compositions and methods of use of orf1358 from beta-hemolytic streptococcal strains
AU2009313615B2 (en) 2008-11-05 2012-11-29 Regents Of The University Of Minnesota Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (BHS) disease
WO2011041003A2 (en) 2009-06-22 2011-04-07 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
AU2010264538B2 (en) 2009-06-22 2013-10-03 Wyeth Llc Immunogenic compositions of Staphylococcus aureus antigens
EP2335730A1 (de) 2009-12-18 2011-06-22 Deutsches Krebsforschungszentrum Fusionspolypeptide und ihre Verwendung zur Vorbeugung und Behandlung von Krebs
EP3626263A1 (de) 2010-06-04 2020-03-25 Wyeth LLC Impstoffformulierungen
CA2808975C (en) 2010-08-23 2018-10-30 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
KR101584871B1 (ko) 2010-09-10 2016-01-22 와이어쓰 엘엘씨 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
HUE033072T2 (hu) 2010-12-22 2017-11-28 Wyeth Llc Staphylococcus aureus antigének immunogén készítményei
ITMI20111182A1 (it) 2011-06-28 2012-12-29 Canio Buonavoglia Vaccino per coronavirus canino
CA2865745C (en) 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CA2879443A1 (en) 2012-07-19 2014-01-23 Zoetis Llc Bovine influenza virus compositions
WO2014018724A1 (en) 2012-07-27 2014-01-30 Zoetis Llc Tick toxin compositions
RU2672053C2 (ru) 2012-12-20 2018-11-09 Пфайзер Инк. Способ гликоконъюгации
EP2941256B1 (de) 2012-12-30 2020-05-06 Carmel-Haifa University Economic Corporation Ltd Makrophagen mit niedrigem cd11b-gehalt und konditionierte medien dafür zur behandlung von krebs und/oder fibrose
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
CA2907098A1 (en) 2013-03-15 2014-09-25 Zoetis Services Llc Cross-protection of bovines against b. trehalosi infection by a multi-valent vaccine
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
WO2016130569A1 (en) 2015-02-09 2016-08-18 Mj Biologics, Inc. A composition comprising pedv antigens and methods for making and using the composition
EP3116539B1 (de) 2014-03-11 2018-10-10 Regents of the University of Minnesota Impfstoffe gegen porzines epidemisches diarrhoevirus und verfahren zur verwendung davon
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
KR20190049940A (ko) 2015-02-19 2019-05-09 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
JP6570648B2 (ja) 2015-03-12 2019-09-04 ゾエティス・サービシーズ・エルエルシー ピオリシン方法及び組成物
KR102143534B1 (ko) 2015-05-04 2020-08-12 화이자 인코포레이티드 B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도
DK3334454T3 (da) 2015-08-14 2022-11-14 Zoetis Services Llc Mycoplasma-Bovis-sammensætninger
CA3010977A1 (en) 2016-01-11 2017-07-20 Zoetis Services Llc Novel cross protective vaccine compositions for porcine epidemic diarrhea virus
US11033615B2 (en) 2016-05-31 2021-06-15 The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland Zika virus vaccine and methods of production
UA125029C2 (uk) 2016-10-05 2021-12-29 Зоетіс Сервісіс Ллк Спосіб ліофілізації, який забезпечує стабільно дегідратовані найпростіші для застосування як ефективних живих вакцин
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
GB201703529D0 (en) 2017-03-06 2017-04-19 Cambridge Entpr Ltd Vaccine composition
CA3155669A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2021211279A1 (en) 2020-04-17 2021-10-21 Regents Of The University Of Minnesota SARS-CoV-2 SPIKE RECEPTOR BINDING DOMAIN AND COMPOSITIONS AND METHODS THEREOF
EP4203995A1 (de) 2020-08-26 2023-07-05 Pfizer Inc. Gruppe-b-streptococcus-polysaccharid-protein-konjugate, verfahren zur herstellung von konjugaten, immunogene zusammensetzungen mit konjugaten und verwendungen davon
EP4241790A1 (de) 2022-03-07 2023-09-13 InnaTher Gene Therapy S.à.r.l. Expressionssystem zur behandlung von krebs
EP4241791A1 (de) 2022-03-07 2023-09-13 InnaTher Gene Therapy S.à.r.l. Kombinierte gen- und strahlentherapie zur behandlung von krebs
KR20250054810A (ko) 2022-09-29 2025-04-23 화이자 인코포레이티드 Rsv f 단백질 삼량체를 포함하는 면역원성 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342828A (en) * 1979-07-20 1982-08-03 Morinaga Milk Industry Co., Ltd. Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells
US4438032A (en) * 1981-01-30 1984-03-20 The Regents Of The University Of California Unique T-lymphocyte line and products derived therefrom
JPS59137417A (ja) * 1983-01-28 1984-08-07 Morinaga Milk Ind Co Ltd 人尿由来コロニ−形成刺激因子及びカリクレインの製造法
JPS59169489A (ja) * 1983-03-15 1984-09-25 Otsuka Pharmaceut Co Ltd ヒト培養株化細胞
AU594014B2 (en) * 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
AU588819B2 (en) * 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
IE59581B1 (en) * 1984-11-20 1994-03-09 Schering Biotech Corp Cdna clones coding for polypeptides exhibiting human granulocyte macrophage and eosinophil cellular growth factor activity
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
DE3545568A1 (de) * 1985-12-21 1987-07-16 Hoechst Ag Gm-csf-protein, seine derivate, herstellung solcher proteine und ihre verwendung

Also Published As

Publication number Publication date
DK382986A (da) 1987-02-17
AU6103186A (en) 1987-02-19
EP0211684B1 (de) 1992-07-08
JPS6289621A (ja) 1987-04-24
EP0211684A2 (de) 1987-02-25
AU586876B2 (en) 1989-07-27
DK174603B1 (da) 2003-07-14
JPH0780781B2 (ja) 1995-08-30
EP0211684A3 (en) 1988-06-08
DK382986D0 (da) 1986-08-11
DE3685918D1 (de) 1992-08-13
DE3685918T2 (de) 1993-02-04
CA1341142C (en) 2000-11-21
US5078996A (en) 1992-01-07

Similar Documents

Publication Publication Date Title
AU586876B2 (en) Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
McKay et al. Epidermal cytokines and their roles in cutaneous wound healing
Gowen et al. Preferential inhibition of cytokine‐stimulated bone resorption by recombinant interferon gamma
Groves et al. Recombinant human GM-CSF in the treatment of poorly healing wounds
Serša et al. Electrochemotherapy: variable anti-tumor effect on different tumor models
ATE81984T1 (de) Verwendung von granulozyt-makrophagen-kolonie erregenden faktor zur herstellung eines medikaments zur behandlung von bakterieller krankheiten.
CZ506785A3 (en) Human tumorous necrotic factor, process of its production, dna encoding the human tumorous necrotic factor, a cell transformed by this dna, agent in which the human tumorous necrotic factor is comprised and agent suitable to treating tumors
DE69333321D1 (de) Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten.
DE69034018D1 (de) Kombinierte verwendung von hyaluronsäure und therapeutischen wirkstoffen zur verbesserung des therapeutischen effekts
DE68910159D1 (de) Dosierform für Verabreichung in der Humanmedizin.
NO880929D0 (no) Produksjon og bruk av il-6.
KR950701226A (ko) C-키트 수용체의 리간드 및 그의 사용방법
ATE247714T1 (de) Antitumor-gentherapie bei immuno-und/oder entzuendungmodulation
EP0325471A1 (de) Verfahren zur Unterbindung des Wachstums von normalen Zellen und Krebszellen
IL77101A (en) Method for purifying a human tnf produced by recombinant dna technique
JPS5699412A (en) Rosemary aciddcontaining pharmaceutic product
Tada et al. Human glioblastoma cells produce 77 amino acid interleukin-8 (IL-877)
Soma et al. Biological Activities of Novel Recombinant Tumor Necrosis Factor Having N-Terminal: Amino Acid Sequences Derived from Cytotoxic Factors Produced by THP-1 Cells
WO1990004977A3 (en) Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon
Rathjen et al. Differential effects of small tumour necrosis factor-alpha peptides on tumour cell cytotoxicity, neutrophil activation and endothelial cell procoagulant activity
Gupta et al. Increased release of interleukin-1 from mouse peritoneal macrophages in vitro after cisplatin treatment
Grimm et al. The lymphokine-activated killer cell phenomenon: in vitro and in vivo studies
IE920070A1 (en) Use of IL-4 to enhance the reparative phase of wound healing and repair and to enhance the healing of infected wounds and the wounds of diabetic mammals
Yip et al. Stimulation of lymphokine production by teleocidin, aplysiatoxin, and debromoaplysiatoxin
Van Moorselaar et al. Combined effects of tumor necrosis factor alpha and radiation in the treatment of renal cell carcinoma grown as spheroids

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time